CDKN2A and heart failure: In anthracycline‐induced accelerated cardiac aging, ACBP/DBI neutralization does not only improve the function of the heart but also reduces the frequency of senescent cells expressing cyclin‐dependent kinase inhibitor 2A (CDKN2A, best known as p16) (Montegut, Joseph, Chen, Abdellatif, Ruckenstuhl, Motino, et al., 2023), which has previously been causatively involved in DOX‐induced cardiac failure (Demaria et al., 2017).